.Attributes Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free as well as total survival, leading to FDA commendation and a brand-new procedure possibility for clients.